Gudrun Schleiermacher

Sensitivity profiling reveals consistent drug responses across preclinical neuroblastoma models

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

The ITCC-P4 PDX platform of pediatric cancers for preclinical testing

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

Differential chromatin response to retinoic acid in neuroblastoma according to type of ATRX mutation

This study shows that ATRX mutation type affects chromatin response to retinoic acid in neuroblastoma, influencing differentiation and therapeutic response.

AP-1 Primes Transcriptional Noise-Led Cancer Treatment Adaptation Through KDM5 Chromatin Rewiring

The paper identifies transcriptional noise as a driver of cancer treatment adaptation through AP-1 and KDM5-mediated chromatin rewiring in neuroblastoma and hepatoblastoma.

Minimally invasive classification of pediatric solid tumors using reduced representation bisulfite sequencing of cell-free DNA: a proof-of-principle study

This study demonstrates that reduced representation bisulfite sequencing of cell-free DNA can accurately classify pediatric solid tumors with high sensitivity.

Clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction

The paper introduces QuantumClone, a method for clonal reconstruction in cancer that accounts for variant allele frequencies and genotypes, and applies it to neuroblastoma samples to identify recurrently altered pathways in different clonal populations.